CANDEL THERAPEUTICS INC (CADL) Stock Price, Quote, News and Overview
NASDAQ:CADL - Nasdaq - US1374041093 - Common Stock - Currency: USD
CADL Quote, Performance and Key Statistics
11.63
-0.58 (-4.75%)
The current stock price of CADL is 11.63 USD. In the past month the price increased by 64.73%. In the past year, price increased by 564.57%.
CADL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CADL
Company Profile
Candel Therapeutics, Inc. is a late clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 42 full-time employees. The company went IPO on 2021-07-27. The firm is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The firm has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Company Info
CANDEL THERAPEUTICS INC
117 Kendrick Street,, Suite 450
Needham MASSACHUSETTS US
CEO: Paul Peter Tak
Employees: 42
Company Website: https://www.candeltx.com/
Investor Relations: https://ir.candeltx.com/
Phone: 16179165445
CANDEL THERAPEUTICS INC / CADL FAQ
What is the stock price of CANDEL THERAPEUTICS INC today?
The current stock price of CADL is 11.63 USD. The price decreased by -4.75% in the last trading session.
What is the ticker symbol for CANDEL THERAPEUTICS INC stock?
The exchange symbol of CANDEL THERAPEUTICS INC is CADL and it is listed on the Nasdaq exchange.
On which exchange is CADL stock listed?
CADL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CANDEL THERAPEUTICS INC stock?
7 analysts have analysed CADL and the average price target is 17.34 USD. This implies a price increase of 49.1% is expected in the next year compared to the current price of 11.63. Check the CANDEL THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CANDEL THERAPEUTICS INC worth?
CANDEL THERAPEUTICS INC (CADL) has a market capitalization of 513.23M USD. This makes CADL a Small Cap stock.
How many employees does CANDEL THERAPEUTICS INC have?
CANDEL THERAPEUTICS INC (CADL) currently has 42 employees.
What are the support and resistance levels for CANDEL THERAPEUTICS INC (CADL) stock?
CANDEL THERAPEUTICS INC (CADL) has a support level at 7.57. Check the full technical report for a detailed analysis of CADL support and resistance levels.
Should I buy CANDEL THERAPEUTICS INC (CADL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CADL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CADL, evaluating the profitability, health, valuation and growth aspects
- CANDEL THERAPEUTICS INC (CADL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CANDEL THERAPEUTICS INC (CADL) Sales and EPS estimates to see what analysts future expectations are.
- CANDEL THERAPEUTICS INC (CADL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CANDEL THERAPEUTICS INC (CADL) Insider and Institutional Ownership to learn about the owners and their transactions.
- CANDEL THERAPEUTICS INC (CADL) Stock Chart to make your own analysis
- CANDEL THERAPEUTICS INC (CADL) Latest news and press-releases to stay up to date.
Does CANDEL THERAPEUTICS INC (CADL) stock pay dividends?
CADL does not pay a dividend.
What is the Price/Earnings (PE) ratio of CANDEL THERAPEUTICS INC (CADL)?
CANDEL THERAPEUTICS INC (CADL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.36).
What is the Short Interest ratio of CANDEL THERAPEUTICS INC (CADL) stock?
The outstanding short interest for CANDEL THERAPEUTICS INC (CADL) is 7.48% of its float. Check the ownership tab for more information on the CADL short interest.
CADL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CADL. When comparing the yearly performance of all stocks, CADL is one of the better performing stocks in the market, outperforming 99.42% of all stocks.
CADL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CADL. CADL may be in some trouble as it scores bad on both profitability and health.
CADL Financial Highlights
Over the last trailing twelve months CADL reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS decreased by -21.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.1% | ||
| ROE | -297.72% | ||
| Debt/Equity | 0.97 |
CADL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CADL. The Buy consensus is the average rating of analysts ratings from 7 analysts.